Immunomedics, Inc. (NASDAQ: IMMU)
Company Name:Immunomedics, Inc.
Stock Symbol:NASDAQ: IMMU
Class Period Start:02/09/2018
Class Period End (inclusive):01/17/2019
Filing Deadline:02/25/2019
According to the Complaint, Immunomedics purports to be a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.
The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts.